Hospital
Oneida Health Systems, INC
Oneida Health Systems, INC was paid $17.62M by Medicaid between Jan 2018 and Dec 2024, across 272 billing codes. Its largest line is 99283, emergency room visit (moderate) — 8.5% of everything it billed.
33Billing provider infoONEIDA HEALTH SYSTEMS, INC
ONEIDA, NY 13421
ONEIDA, NY 13421
33aNPI1962408203assigned 06/22/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.62M
24GClaims519,731
24DCodes billed272
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#65 of 231
Median peer was paid$561K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,352 | $38K | |
| 2019 | 25,593 | $834K | |
| 2020 | 89,452 | $3.02M | |
| 2021 | 110,593 | $3.64M | |
| 2022 | 110,633 | $3.57M | |
| 2023 | 108,524 | $3.91M | |
| 2024incomplete | 73,584 | $2.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 11,350 | 10,877 | $1.50M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.7% | 14,560 | 12,373 | $1.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 10,877 | 10,185 | $1.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 9,140 | 8,796 | $1.18M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.6% | 4,656 | 4,146 | $991K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 3,757 | 3,657 | $980K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.4% | 8,867 | 8,297 | $948K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.5% | 6,752 | 6,334 | $619K |
| 80053 | Comprehensive metabolic panel | 3.2% | 31,730 | 28,530 | $562K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.2% | 1,121 | 1,115 | $559K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 1,821 | 1,795 | $505K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 7,522 | 2,165 | $453K |
260 more codes
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.5% | 680 | $440K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 1,501 | $412K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.9% | 1,214 | $339K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.9% | 6,732 | $334K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 13,087 | $291K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 2,373 | $288K |
| 59025 | Fetal non-stress test | 1.2% | 1,338 | $218K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 995 | $170K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,252 | $168K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 106 | $161K |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,402 | $158K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,306 | $131K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 417 | $125K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,047 | $106K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,111 | $104K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,029 | $99K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,722 | $95K |
| 97161 | <1% | 1,125 | $93K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,168 | $89K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,116 | $85K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 116 | $81K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,241 | $78K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,654 | $65K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,089 | $60K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,844 | $60K |
| 80061 | Lipid panel | <1% | 8,557 | $59K |
| 88142 | <1% | 2,584 | $54K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,247 | $53K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 208 | $52K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,667 | $51K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,586 | $49K |
| 87088 | <1% | 9,886 | $48K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 604 | $48K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,906 | $47K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,553 | $46K |
| 87660 | <1% | 3,846 | $45K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 510 | $43K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 401 | $43K |
| 99201 | <1% | 409 | $42K | |
| 88342 | <1% | 853 | $42K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 317 | $42K |
| 84439 | <1% | 4,734 | $41K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,482 | $40K |
| 86850 | <1% | 2,303 | $40K | |
| 87480 | <1% | 3,526 | $40K | |
| 87510 | <1% | 3,320 | $37K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 303 | $35K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 103 | $35K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 368 | $35K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,572 | $35K |
| 83880 | <1% | 1,091 | $33K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 299 | $33K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 703 | $32K |
| 86901 | <1% | 2,450 | $31K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,888 | $30K |
| 83655 | <1% | 2,291 | $29K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 251 | $29K |
| 82607 | <1% | 2,521 | $28K | |
| 76641 | <1% | 1,362 | $28K | |
| 86900 | <1% | 2,451 | $28K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,837 | $25K |
| 82728 | <1% | 2,038 | $25K | |
| 90686 | <1% | 1,040 | $24K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 170 | $23K |
| 87634 | <1% | 2,077 | $23K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 205 | $23K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 199 | $22K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 534 | $22K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 212 | $21K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 469 | $20K |
| 87077 | <1% | 3,560 | $20K | |
| 94060 | <1% | 238 | $20K | |
| 86141 | <1% | 2,616 | $19K | |
| 73564 | <1% | 1,757 | $19K | |
| 93971 | <1% | 301 | $18K | |
| 87070 | <1% | 2,682 | $17K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $17K |
| 81025 | <1% | 5,388 | $17K | |
| 84153 | <1% | 957 | $16K | |
| 84403 | <1% | 643 | $16K | |
| 71250 | <1% | 211 | $15K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 100 | $15K |
| 86803 | <1% | 1,656 | $14K | |
| 87186 | <1% | 3,201 | $14K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 123 | $14K |
| 87340 | <1% | 1,503 | $14K | |
| 84702 | <1% | 1,751 | $13K | |
| 85027 | <1% | 5,221 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 57 | $13K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 122 | $13K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 37 | $13K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,936 | $12K |
| 80076 | <1% | 1,200 | $11K | |
| 76536 | <1% | 576 | $11K | |
| 90715 | <1% | 519 | $11K | |
| 86762 | <1% | 829 | $11K | |
| 86618 | <1% | 778 | $11K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 258 | $11K |
| 83540 | <1% | 2,350 | $10K | |
| 99441 | <1% | 96 | $10K | |
| 87081 | <1% | 2,213 | $10K | |
| 73630 | <1% | 1,754 | $9K | |
| 88304 | <1% | 271 | $9K | |
| 99292 | <1% | 167 | $9K | |
| 73610 | <1% | 1,796 | $8K | |
| 72110 | <1% | 590 | $8K | |
| 96415 | <1% | 13 | $8K | |
| 73110 | <1% | 1,452 | $8K | |
| 81001 | <1% | 8,117 | $8K | |
| 90682 | <1% | 328 | $8K | |
| 73030 | <1% | 1,288 | $8K | |
| 82784 | <1% | 720 | $7K | |
| 81003 | <1% | 12,305 | $7K | |
| 83735 | <1% | 3,902 | $7K | |
| 73130 | <1% | 1,382 | $7K | |
| 76801 | <1% | 126 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,592 | $7K |
| 83550 | <1% | 1,505 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,550 | $6K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 474 | $6K |
| H0049 | Alcohol and/or drug screening | <1% | 183 | $6K |
| 85610 | <1% | 2,693 | $6K | |
| 74018 | <1% | 1,298 | $6K | |
| 86665 | <1% | 296 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,397 | $6K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 360 | $6K |
| 86592 | <1% | 1,869 | $6K | |
| 84466 | <1% | 534 | $6K | |
| 85007 | <1% | 3,488 | $5K | |
| 82746 | <1% | 456 | $5K | |
| 12001 | <1% | 12 | $5K | |
| 12002 | <1% | 12 | $5K | |
| 85652 | <1% | 2,449 | $4K | |
| 84480 | <1% | 704 | $4K | |
| 83690 | <1% | 5,098 | $4K | |
| 72141 | <1% | 12 | $3K | |
| H1000 | Prenatal care, at-risk assessment | <1% | 113 | $3K |
| 85730 | <1% | 1,804 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 74 | $3K |
| 86003 | <1% | 52 | $3K | |
| 94726 | <1% | 45 | $3K | |
| 70486 | <1% | 25 | $3K | |
| 82043 | <1% | 629 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,869 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 67 | $3K |
| 86703 | <1% | 183 | $3K | |
| 82248 | <1% | 571 | $3K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 24 | $3K |
| 71271 | <1% | 100 | $2K | |
| 86664 | <1% | 169 | $2K | |
| 86038 | <1% | 511 | $2K | |
| 90734 | <1% | 66 | $2K | |
| 84550 | <1% | 672 | $2K | |
| 86663 | <1% | 170 | $2K | |
| 86431 | <1% | 447 | $2K | |
| 86039 | <1% | 421 | $2K | |
| 83001 | <1% | 105 | $2K | |
| 84146 | <1% | 110 | $2K | |
| 96367 | <1% | 35 | $2K | |
| 86617 | <1% | 120 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 374 | $2K |
| 94729 | <1% | 45 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 29 | $2K |
| 86706 | <1% | 184 | $2K | |
| 87045 | <1% | 220 | $2K | |
| 90673 | <1% | 78 | $2K | |
| 84703 | <1% | 1,661 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 638 | $2K |
| 87631 | <1% | 25 | $2K | |
| 82950 | <1% | 538 | $2K | |
| 86308 | <1% | 490 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,467 | $1K |
| 85018 | <1% | 798 | $1K | |
| 87899 | <1% | 207 | $1K | |
| 84100 | <1% | 885 | $1K | |
| 85379 | <1% | 1,035 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $1K |
| A6010 | Collagen based wound filler, dry form, sterile, per gram of collagen | <1% | 42 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,545 | $1K |
| 73080 | <1% | 253 | $1K | |
| 87040 | <1% | 1,660 | $1K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 28 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 132 | $1K |
| 73562 | <1% | 109 | $1K | |
| 86709 | <1% | 140 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $981.72 |
| 82550 | <1% | 417 | $967.80 | |
| 85014 | <1% | 455 | $940.94 | |
| 86705 | <1% | 126 | $923.87 | |
| 99173 | <1% | 12 | $835.08 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $763.56 |
| 73502 | <1% | 153 | $716.84 | |
| 86480 | <1% | 12 | $645.94 | |
| 0012A | <1% | 45 | $595.35 | |
| 82105 | <1% | 94 | $593.86 | |
| 82150 | <1% | 159 | $560.65 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 21 | $558.81 |
| 84484 | <1% | 3,865 | $548.83 | |
| 87328 | <1% | 37 | $462.82 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 29 | $448.55 |
| 86235 | <1% | 14 | $440.66 | |
| 87329 | <1% | 37 | $389.87 | |
| 87177 | <1% | 51 | $379.89 | |
| 83615 | <1% | 90 | $335.10 | |
| 81002 | <1% | 3,010 | $328.99 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,032 | $303.11 |
| 82962 | <1% | 2,888 | $289.12 | |
| A4213 | Syringe, sterile, 20 cc or greater, each | <1% | 1,613 | $282.94 |
| 90651 | <1% | 12 | $255.85 | |
| 87209 | <1% | 51 | $252.64 | |
| 83993 | <1% | 26 | $239.19 | |
| 83605 | <1% | 1,414 | $228.98 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 957 | $228.56 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 31 | $206.03 |
| 76882 | <1% | 13 | $202.11 | |
| 73590 | <1% | 40 | $192.48 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 13 | $180.88 |
| 0011A | <1% | 13 | $175.70 | |
| 73140 | <1% | 70 | $153.60 | |
| 82977 | <1% | 42 | $150.88 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,282 | $150.31 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,648 | $129.50 |
| 82565 | <1% | 29 | $125.75 | |
| 80305 | <1% | 516 | $125.45 | |
| 87420 | <1% | 17 | $99.41 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,398 | $96.51 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,364 | $80.17 |
| 87101 | <1% | 12 | $69.39 | |
| 86225 | <1% | 16 | $63.01 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,202 | $62.44 |
| 84460 | <1% | 12 | $50.80 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 772 | $50.21 |
| 84520 | <1% | 12 | $47.40 | |
| 96376 | <1% | 353 | $45.05 | |
| 89055 | <1% | 12 | $34.03 | |
| 71101 | <1% | 12 | $31.83 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 21 | $27.90 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 86 | $24.83 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,926 | $16.06 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,084 | $13.51 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 476 | $8.53 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 366 | $6.80 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,558 | $3.61 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 88 | $2.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,896 | $2.20 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 189 | $1.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 323 | $0.60 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 12 | $0.00 |
| A4615 | Cannula, nasal | 0% | 17 | $0.00 |
| 95806 | 0% | 26 | $0.00 | |
| 88300 | 0% | 14 | $0.00 | |
| 96127 | 0% | 40 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 12 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 52 | $0.00 |
| 87430 | 0% | 49 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 14 | $0.00 |
| 59430 | 0% | 13 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 12 | $0.00 |
| 90461 | 0% | 90 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOERNIG, FELISSA (CEO/PRESIDENT)